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 ABSTRACT 
 
Background/Aims 
 
In 2013, as part of our genetic investigation of patients with Inherited Retinal 
Disease, we utilised multigene panel testing of 105 genes known to cause 
retinal disease in our patient cohorts. This test was performed in a UK 
National Health Service (NHS) accredited laboratory.  
 
Method 
 
The results of all multigene panel tests requested between 1.4.13 and 31.8.14 
were retrospectively reviewed. All patients had been previously seen at 
Moorfields Eye Hospital, London, UK and diagnosed with an inherited retinal 
dystrophy after clinical examination and detailed retinal imaging. 
 
Result 
 
The results were categorised into three groups: 1) Testing helped establish a 
certain molecular diagnosis in 45/115 (39%). Variants in USH2A (n=6) and 
RP1 (n=4) were most common.  
2) Definitive conclusions could not be drawn from molecular testing alone in   
13/115 (11%) as either insufficient pathogenic variants were discovered or 
those identified that were not consistent with the phenotype.  
3) Testing did not identify any pathogenic variants responsible for the 
phenotype in 57/115 (50%).  
 
Conclusion 
 
Multigene panel testing performed in an NHS setting has enabled a molecular 
diagnosis to be confidently made in 40% of cases. Novel variants accounted 
for 38% of all identified variants. Detailed retinal phenotyping helped the 
interpretation of specific variants. Additional care needs to be taken when 
assessing polymorphisms in genes that have been infrequently associated 
with disease, as historical techniques were not as rigorous as contemporary 
ones. Future iterations of sequencing are likely to offer higher sensitivity, 
testing a broader range of genes, more rapidly and at a reduced cost.  
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 INTRODUCTION 
 
 
Inherited retinal disorders (IRD) are a genetically heterogeneous group of 
conditions, almost all of which are currently untreatable. They are associated 
with significant ocular morbidity and so, despite their low overall prevalence, 
they are a common cause of severe visual loss. In England and Wales they 
now represent the commonest cause of sight impairment registration in adults 
of working age [I], and the second commonest in childhood [II]. Managing 
patients with rare diseases requires specific expertise and for IRD this 
includes access to diagnostic genetic testing, a field that has rapidly evolved 
over the past decade. 
 
The initial ophthalmic genetic discoveries were made in a research setting, 
using linkage analysis followed by Sanger sequencing [III, IV]. As a result, 
sequencing of single genes was subsequently offered as a clinical test. This 
technique still retains great utility for a few IRD where the phenotype is readily 
recognisable and where there is no or limited genetic heterogeneity (e.g. 
BEST1 and RS1) and for regions not amenable to novel sequencing methods 
(e.g. ORF15 of RPGR and OPN1LW/OPN1MW). Sanger sequencing is 
however time consuming and costly, making it impractical for testing multiple 
genes in a large number of patients; there are over 300 genes currently 
associated with IRD. Subsequently genotyping technologies were developed 
which were capable of detecting hundreds of known sequence variants 
simultaneously (the Affymetrix array; Affymetrix, Santa, Clara, CA; Illumina 
platform; Illumina, San Diego, CA; or the Arrayed Primer Extension (Apex) 
chip; Asper Ophthalmics, Ltd., Tartu, Estonia) [V]. Whilst this approach offers 
a rapid and cost-effective form of analysis, it is limited to identifying only 
known disease-associated variants.  
 
More recently it has become possible to rapidly sequence whole genes 
simultaneously, using massively parallel sequencing techniques (Next 
Generation Sequencing, NGS). In order to maximise effectiveness, both in the 
quality of information derived and cost, limiting sequencing to the coding 
regions of genes known to cause IRD has been performed. This “targeted 
capture” approach, also known as focussed exome sequencing or multigene 
panel testing, has been utilised in a clinical diagnostic setting in preference to 
whole exome sequencing. Whilst the former technique has key advantages, 
the main drawback is that the number of genes captured is limited by current 
knowledge, and may miss variants in novel genes, thus requiring regular 
updating. Despite these limitations, recent studies have reported diagnostic 
rates of approximately 50%, significantly higher than had been obtained with 
previous technologies [VI-X]. These reports have however generally involved 
only small numbers of patients. 
 
In 2013, as part of our genetic investigation of patients with IRD, we utilised 
focused exome sequencing of 105 genes known to cause retinal disease in 
our patient cohorts. This test was performed in a National Health Service 
(NHS) accredited laboratory (National Genetics Reference Laboratory 
(NGRL), Manchester University Teaching Hospitals NHS Trust) as part of 
 routine clinical care and was not part of a research study. The present work 
describes the results of multigene panel testing in this cohort, and how it has 
influenced our clinical practice.  
 
 
MATERIALS AND METHODS 
 
 
Clinical cohort investigated 
The results of all genetic tests (NGS, 105 genes) requested between 1.4.13 
and 31.8.14 were retrospectively reviewed. All patients had been examined in 
the IRD clinics by one of three experienced clinicians (ATM, ARW, MM) at 
Moorfields Eye Hospital, London, UK and diagnosed with IRD. In order to 
refine the diagnosis, all patients consented to further genetic testing which 
was then requested in accordance with the retinal phenotype. Where a 
specific gene (e.g. BEST1, RS1, NR2E3, RDH12, CRB1), or small group of 
genes were suspected (e.g. ABCA4, PRPH2), patients were not subjected to 
the full 105 gene screen, as Sanger sequencing was requested. Patients with 
albinism, isolated foveal hypoplasia and inherited optic neuropathies were 
similarly not investigated by this route.  Retinal dystrophies occurring as part 
of a syndromic diagnosis were included.  
 
Genetic testing 
A custom designed Sure Select Target Enrichment Kit (Agilent Technologies, 
Santa Clara, CA, USA) was used for targeted enrichment of 105 genes known 
to be mutated in patients with isolated and syndromic retinal disease. 
Samples were run on a SOLiD 4 sequencer (Life Technologies, Grand Island, 
NY, USA). The sequencing and variant calling methodologies have previously 
been reported [VIII]. The testing laboratory issued a clinical report detailing 
variants thought to account for the disease. If a novel variant was identified, a 
further comment as to their predicted pathogenicity and evolutionary 
conservation was also offered and segregation studies performed.  
 
 
RESULTS 
 
 
In 17 months, 115 multigene panel tests were requested. The results were 
available in all cases. Our findings have been grouped into three major 
categories: 
 
1). Testing helped to establish a certain molecular diagnosis. 
A specific molecular genetic diagnosis was identified in 45/115 (39%). This 
allowed the clinician to more confidently counsel the patient regarding the 
cause of their disease, inheritance pattern and therefore recurrence risk. In 
the majority of cases (28/45) variants already known to cause retinal disease 
were discovered. However, in over a third of cases, either one or both alleles 
harboured novel genetic variants that were predicted to be damaging (Table 
I). Variants in USH2A (n=6) and RP1 (n=4) were most commonly identified, 
and together represented 22% of all cases. The remainder (78%) resulted 
 from variants in a total of 24 genes, with no one gene responsible for more 
than 4% of cases, underlining the genetically heterogeneous nature of IRD. 
 
Pathogenic variants in ABCA4, PRPH2 and PROM1 were also identified, 
perhaps unexpected, as a separate testing pathway existed for macular 
dystrophies. Similarly one may have predicted that RPGR related RP may 
have been suspected from the pedigree structure or clinical features (e.g. 
early onset, severe disease, association with myopia, carrier changes in 
females). However, in all of these cases patients presented with typical, 
simplex retinitis pigmentosa, with no overt signs directing the investigating 
clinician towards a specific molecular diagnosis (Figure I). 
 
 
2). Definitive conclusions could not be drawn from molecular testing alone.  
In 13/115 (11%) patients genetic testing identified potentially pathogenic 
variants, but overall the results were thought to be inconclusive, as a definitive 
molecular diagnosis (from this test alone) could not be established. In the 
majority of cases (10/13 = 77%) only one of two recessive alleles was 
identified in patients thought to have a recessively inherited retinal dystrophy. 
In two of these (Patients 31953 and 32703), single alleles, known to be 
pathogenic from prior reports were identified in CRB1 [XI-XIII]. For patient 
31953 careful clinical phenotyping was helpful in supporting the hypothesis 
that CRB1 was indeed the causative gene as this case demonstrated typical 
optical coherence tomography (OCT) characteristics quite specific to this 
gene (Figure II). Patient 32703 however did not exhibit any of these classical 
features and consequently was considered unsolved. In a minority of cases 
(3/13), a sufficient number of variants were identified however their 
pathogenicity was questionable (PITPNM3, RDH12, PROM1) (Table II). 
 
 
3). Testing did not identify any pathogenic variants responsible for the 
phenotype. 
In 57/115 (50%) cases testing did not identify any genetic variants that were 
thought to result in retinal disease. In one case a negative test was 
considered sufficient investigation to rule out a genetic aetiology, offering 
greater confidence to the diagnosis of acute zonal occult outer retinopathy 
(AZOOR). In all other cases the causative variants were considered elusive 
and a more comprehensive genetic study was undertaken with patients 
invited into whole exome (BRIDGE SPEED Project) or whole genome 
sequencing studies (100,000 Genomes Pilot Project, Genomics England, UK).  
 
 
DISCUSSION 
 
The present study has investigated the sensitivity of a specific focused 
exome-sequencing pipeline in a cohort of preselected patients with inherited 
retinal disease. This work represents the largest examination of such a 
technique, where patients have been recruited from a single clinical centre. 
115 patients were tested, in whom the clinical phenotype had not suggested a 
candidate gene to screen. Pathogenic variants were identified in 45 cases. A 
 single pathogenic allele was identified in one patient which, when combined 
with additional phenotypic information established a definitive diagnosis. 
Overall therefore genetic testing enabled a diagnosis to be made in 46/115 
(40%) cases where experienced clinical examiners could not establish a 
specific genetic diagnosis on phenotypic features alone.  
 
Of the 46 confidently solved cases, 28 had recessive disease, 17 autosomal 
dominant disease and a single case of X-linked disease (patient 31664). In 
the majority of cases these inheritance patterns were not predicted from the 
family pedigree, as simplex cases are uninformative and dominant inheritance 
may be underestimated due to non-penetrance, particularly prevalent with 
variants of the splicing factors PRPF8 and PRPF31. Similarly, autosomal 
recessive inheritance may be confused with autosomal dominant disease 
when two successive generations are affected, not an uncommon occurrence 
for genes where the carrier frequency for mutant alleles is high e.g. ABCA4. 
Herein pseudodominance was also observed in pedigree 20929 harbouring 
USH2A variants (Figure IIIa). The identification of X-linked disease in Patient 
31664 was also surprising as this pedigree was predicted to segregate a 
dominant variant (Figure IIIb). The mother and son were both affected, 
however the maternal phenotype was particularly severe, even at a relatively 
young age, not thereby suggestive of typical RPGR-related retinopathy. 
Testing therefore provided the opportunity for more accurate genetic 
counselling.  
 
Retinitis pigmentosa (RP) can occur either in isolation or as part of a 
syndrome, although this may not always be clear at the time of ophthalmic 
assessment. NGS has particular utility in the diagnosis of syndromic disease, 
especially where the extraocular phenotype may appear subclinical at first 
presentation [XIV]. Here we have identified two cases of syndromic disease – 
both patients with Usher Syndrome (USH). As patient 31899 and two of her 
affected siblings display the classical USH type 1 (USH1) phenotype, the 
identification of bi-allelic MYO7A variants, one of the five genes known to 
cause USH1, was not unexpected [XV-XX]. The gene responsible for the 
commonest cause of USH type 2 (USH2) is also the commonest cause of 
autosomal recessive isolated RP – USH2A (Daiger 207 [XXI]). Recently it has 
additionally been associated with RP and late onset hearing loss, a 
combination not originally described by von Gräfe and Usher (case D23 [XXII-
XXIV]). The clinical interpretation of USH2A variants is therefore not 
straightforward, as variant may be associated with a wide range of hearing 
problems, and for those with isolated RP it may be uncertain if auditory 
problems will develop later. Here Patient 3381, with a clinical phenotype of RP 
and adult-onset hearing loss was found to carry alleles associated with both 
isolated RP (p.Cys934Trp) and USH2 (p.Arg4192His). As larger cohorts of 
well-characterised patients undergo NGS our understanding of allelic 
hierarchy in USH2A will improve, facilitating accurate genetic counseling. 
Unexpectedly, the same lady was also found to be a carrier for PCDH15, an 
USH1 gene, and a null allele in RPGR (p.Arg449*), highlighting that even with 
focused exome sequencing ‘incidental’ findings will be discovered and pose 
diagnostic challenge. A further cause of USH2 is variant of GPR98 and we 
identified a patient with RP and a single heterozygous variant predicted to 
 introduce a cryptic splice site (Patient 3109; p.Asn157Ser). Although not 
formally tested with audiometry this patient did not report clinically significant 
hearing loss, an important feature to note, as to date all pathogenic variants in 
GPR98 have been associated with dual sensory impairment [XXV]. The 
clinical information in this case therefore suggests that the cause of this 
patient’s retinal dystrophy may be due to variants within of another gene. The 
alternative hypothesis, that mutation of GPR98 is a hitherto unreported cause 
of isolated RP and a second allele is yet to be found, seems less likely.  
As NGS offers an unbiased testing approach, identifying pathogenic variants 
in uncommon retinal disease genes is made easier, where previous candidate 
gene sequencing strategies would have delayed their discovery. This was 
particularly relevant for several genes included in the panel. Mutation of 
PDE6G has thus far been reported to cause RP in only a single Middle 
Eastern pedigree [XXVI]. Whilst PDE6G is an excellent candidate gene for 
retinal disease, the paucity of subsequent reports strengthening the 
association with RP leave the original conclusions open to scrutiny. We now 
record the second case of PDE6G related RP (Patient 30120). This family 
was also noteworthy as they were thought to segregate a dominant disease 
causing allele, as the proband’s late mother, three of eight siblings and a 
niece were reported to be similarly affected, although none had been 
examined. NGS testing in this family not only facilitated the detection of bi-
allelic variants in PDE6G, but also allowed the recurrence risk of disease to 
be downgraded from 50% to less than 1% for future generations.  
 
Another rare cause of RP is heterozygous mutation of KLHL7 (OMIM 612943) 
and both reports to date suggest that this is characterised by late onset 
disease [XXVII, XXVIII]. Here we have identified two patients with variants in 
KLHL7. The previously observed variant (p.Ala153Val) is again seen with 
onset of symptoms at an older age (Patient 28569), whilst the novel variant 
(p.Val141Ala) is associated with a much earlier onset (Patient 28819), 
resulting in significant visual field constriction (to approximately 5-10 degrees) 
and severe symptoms prior to the age of 30. These data highlight the cautious 
approach necessary when attempting to predict phenotypic outcomes from 
patients’ genotype, especially with small cohorts of patients.  
 
Mutation of PITPNM3 (c.1878G>C, p.Gln626His) has also been identified to 
cause cone and cone-rod dystrophy, however since the original report in 2007 
no further groups have replicated these findings [XXIX, XXX]. Here NGS 
identified the same sequence variant in 1/115 patients tested (Patient 32296), 
but this did not segregate with disease and despite acknowledgement of 
variable penetrance in the original report we could not confidently assign 
pathogenicity to this polymorphism. This same nucleotide change has also 
been observed in patients with IRD who are known to carry variants in other 
RP associated genes, and has also been identified in unaffected control 
samples (in-house databases, inherited retinal disease consortium, UK). 
Furthermore, this variant is observed at higher than expected frequencies in 
publically held databases (exome variant sever G/C: 36, C/C: 6467; 1000 
genomes file shows global frequencies G/C: 5: C/C: 1087 accessed 1.7.15). It 
therefore remains likely that the genetic basis for retinal disease in Patient 
 32296 remains unexplained and that PITPNM3 is yet to be confirmed as a 
disease-associated gene. Similarly the pathogenicity of the heterozygous 
variant in RDH12 (Patient 32458) remains outstanding, as again only a single 
report exists [XXXI].  
 
It is important to note that in 60% of our cases a clear molecular diagnosis 
was not obtained. In part this relates to the techniques involved. Whilst 
accurate at the time of design, the exponentially increasing rate of novel 
genetic discoveries means that the capture reagent, designed here to report 
on 105 genes, soon needs updating. Accordingly the latest version has been 
designed to cover 176 disease-associated genes. Even since then a further 
62 genes have been discovered [XXXII]. The disadvantages of multigene 
panel testing are however offset by the accuracy, cost-effectiveness and 
speed that this technique offers, advantages that have allowed its use in a 
clinical rather than solely a research setting. Even if whole exome sequencing 
is performed, we still would not have a test with 100% sensitivity. Intronic and 
intergenic nucleotides, areas that are known to contain regulatory elements, 
would still not be sequenced and many structural variants would also be 
missed, even within the regions captured. As expected therefore, if these 
regions are interrogated, variant detection is improved. This was highlighted 
by Steele-Stallard and colleagues, who have reported finding 35% of missed 
second alleles in USH2A after screening for duplications, deletions and a 
common intronic variant [XXIII]. Whole genome sequencing will offer 
improved sensitivity but currently the costs involved limit its wider use. 
Irrespective of the capture reagent (multigene panel, whole exome or whole 
genome), one additional benefit of NGS platforms is the great “depth” of 
coverage that it offers, as each nucleotide is sequenced many times in 
parallel.  This provides a bioinformatic opportunity to assess the relative 
number of allele counts in a more quantitative way than is possible with 
Sanger sequencing. Here the aforementioned RPGR variant load in Patient 
3381 varied from that expected in the heterozygous state (approximately 
50:50, wt:mt), findings that were confirmed by capillary sequencing, strongly 
suggesting that this patient is a mosaic for this variant (often associated with 
de novo somatic variant).  
 
Although the advantages of NGS are many, we feel that there is still a role for 
Sanger sequencing, especially when one polymerase chain reaction may 
suffice (eg. PROM1 p.Arg373Cys, C1QTNF5 p.Arg163Ser, EFEMP1 
p.Arg345Trp). In a further subset of patients ancillary clinical tests may help 
direct genetic testing (eg. electroretinography for NR2E3 and KCNV2,  
electrooculography for BEST1, fundus autofluorescence for ABCA4), however 
the costs associated with sequencing even a small gene may now not 
compare favourably to those for NGS. It is important to remember that as this 
cohort of patients were excluded from the present study the mutation 
detection rate may have artificially been lowered, as from a genetic point of 
view the “low hanging fruit” will have already been harvested. This hypothesis 
may be tested by comparing our results with those from two large, recently 
reported studies, where patients with recognisable genotypes were included 
(XXXIV, XXXV). The first tested 562 patients, recruited from multiple 
international clinics, finding a sufficient number of pathogenic alleles in 45% of 
 cases. In a further 5% a missed second allele was thought to have evaded 
detection (XXXIV). The second study tested 292 patients, again as part of an 
international collaboration but this time enriched for consanguineous 
pedigrees. A molecular genetic result was obtained in 60% (XXXV). These 
findings also highlight how both the ethnic background and pedigree structure 
of the study population can influence mutation detection rate, in addition to the 
underlying gene of interest. 
 
In summary, the use of multigene panel testing performed in an NHS setting 
has enabled a molecular diagnosis to be confidently made in 40% (46/114) of 
cases. Novel variants accounted for 38% of all identified variants, although as 
testing becomes commonplace this figure is likely to reduce, aiding 
bioinformatics analysis. Obtaining a positive test result facilitated accurate 
counselling, often changing the estimated recurrence risk for future 
generations. Despite our current inability to initiate proven therapeutic 
interventions in the majority of cases many patients still place a high value on 
establishing a biological cause for their symptoms. Furthermore, as there are 
multiple planned and on-going clinical trials for IRD, obtaining a genetic 
diagnosis is likely to be necessary for enrolment [XXXVI]. Future iterations of 
this technique are likely to offer higher sensitivity, testing a broader range of 
genes, more rapidly and at a reduced cost.  
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LEGENDS 
 
Table I: Novel Mutations identified in this study. Where compound 
heterozygous variants are identified, and only one is novel, the previously 
reported variant is shown in parentheses. 
 
Table II: Genetic variants of questionable pathogenicity 
 
Figure I: Colour fundus images from patients with pathogenic mutations in 
ABCA4, PROM1, PRPH2 and RPGR demonstrating signs typical of Retinitis 
Pigmentosa – pigment migration into the retina, retinal arteriolar attenuation 
and optic disc pallor. 
 
Figure II: OCT phenotype of two patients with heterozygous CRB1 mutations 
and missed second allele. Macular thickening without significant oedema and 
relative loss of normal retinal lamination is highly indicative of CRB1-related 
retinopathy (2a,b) - whilst in the absence of these, or other stereotypical 
features, other genetic causes of RP cannot be excluded (2c,d). 
 
Figure IIIA: Pedigree for Patient 20929. As the presence of two affected family 
members in different generations is unusual for rare, recessively inherited 
disorders this family were thought to harbour a dominant allele transmitted 
with variable penetrance. Genetic testing proved this hypothesis incorrect, 
identifying bi-allelic mutation of USH2A as the cause. 
 
Figure IIIB: Pedigree for Patient 31664. As more females than males are 
affected, and some at a young age, autosomal dominant rather than X-linked 
disease was suspected. This family are now known to segregate a pathogenic 
variant in RPGR. 
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Table I 
 
Patient ID Gene Novel mutation 
28819 KLHL7 c.422T>C, p.Val141Ala 
31899 
MYO7A 
c.3728C>T, pProl1243Leu; 
(c.3476G>T, p.Gly1159Val) 
30120 PDE6G c.109C>T, p.Gln37* 
3083 PRPF8 c.5804G>A, p.Arg1935His 
27967 
RP1 
c.4576G>T, p.Glu1526* 
homozygous 
31602 
RP1 
c.5446T>C, p.Cys1816Arg 
heterozygous 
31735 RP1 c.2749C>T, p.Gln917* 
31169 
RPGRIP1 
c.2608_2609insA 
homozygous 
5041 
TULP1 
c.1313G>C, p.Arg438Pro 
heterozygous 
3501 
USH2A 
c.8079G>A, p.Trp2693*; 
(c.12575, p.Arg4192His) 
27978 
USH2A 
c.10342G>A, p.Glu3348Lys 
and c.14803C>T, 
p.Arg4935*; (c.6670G>T, 
p.Gly2224Cys) 
30787 
C2orf71 
c.2315_2321delinsAAG 
homozygous 
22588 
CEP290 
c.148C>T, p.His50Tyr; 
(c.4393C>T, p.Arg1465*) 
32452 EYS c.5928-2A>G homozygous 
3259 
MERTK 
c.345C>G, p.Cys115Trp; 
c.634A>C, p.Thr212Pro 
32408 
IMPG2 
c.3056G>A, p.Cys1019Tyr; 
(c.2716C>T, pArg906*) 
29709 
IMPG2 
c.3113G>T, p.Cys1038Phe; 
(c.3423-7_3423-4delCTTT) 
 
 
 
 
Table II 
 
Gene ID Variant Reason to question 
pathogenicity 
PITPNM3 32296 c.1878G>C, 
p.Gln626His 
heterozygous 
Identified in many 
control samples 
RDH12 32458 c.763delG heterozygous Doesn't fully segregate 
with disease 
PROM1 1796 c.1414C>T, p.Arg472* A dominant pedigree 
with a single recessive 
allele 
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Figure Ia ABCA4 
 
 
Figure Ib PROM1 
 
 
Figure Ic PRPH2 
 
 
 
 
Figure Id PRPH2 
 
 
 
 
Figure Ie RPGR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II 
 
 
 
Figure II OCT RE, LE patient 31953 
 
 
Figure II OCT RE, LE patient 32703 
 
 
 
Figure IIIa 
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